Click for best price
Nonalcoholic Steatohepatitis Market Size, Share 2024
| Market size in 2023 |
US$ 2388.1 million
|
Forecast Market size by 2030 |
US$ 9466.4 million
|
| Growth Rate |
CAGR of 21.7% |
Number of Pages |
110 Pages |
This research report provides a comprehensive analysis of the Non-alcoholic Steatohepatitis market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Non-alcoholic Steatohepatitis market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Non-alcoholic Steatohepatitis, challenges faced by the industry, and potential opportunities for market players.
The global Non-alcoholic Steatohepatitis market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Non-alcoholic Steatohepatitis market presents opportunities for various stakeholders, including Oral, Parenteral. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Non-alcoholic Steatohepatitis market. Additionally, the growing consumer demand present avenues for market expansion.
The global Non-alcoholic Steatohepatitis market was valued at US$ 2388.1 million in 2023 and is projected to reach US$ 9466.4 million by 2030, at a CAGR of 21.7% during the forecast period.
NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage, typically occurring in individuals who do not consume excessive alcohol. Several factors are driving the growth of the NASH market. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, is contributing to the increasing incidence of NASH. Unhealthy lifestyles, sedentary habits, and poor dietary choices are leading to a higher risk of developing NASH, creating a substantial patient population in need of diagnosis and treatment. Secondly, the improved understanding and awareness of NASH among healthcare professionals and the general population have resulted in increased diagnosis rates. As the medical community recognizes the long-term complications and progression of NASH, there is a greater emphasis on identifying patients with NASH and implementing appropriate management strategies.
Key Features:
The research report on the Non-alcoholic Steatohepatitis market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Non-alcoholic Steatohepatitis market.
Market Overview: The report provides a comprehensive overview of the Non-alcoholic Steatohepatitis market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Solid, Liquid), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Non-alcoholic Steatohepatitis market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Non-alcoholic Steatohepatitis market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Non-alcoholic Steatohepatitis market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Non-alcoholic Steatohepatitis market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Non-alcoholic Steatohepatitis market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Non-alcoholic Steatohepatitis market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Non-alcoholic Steatohepatitis, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Non-alcoholic Steatohepatitis market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
- Non-alcoholic Steatohepatitis market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Market segment by Application
Global Non-alcoholic Steatohepatitis Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- AstraZeneca
- Pfizer
- GSK
- Novo Nordisk
- Roche
- AbbVie
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Gilead
- Intercept pharma
- Non-alcoholic Steatohepatitis
- Takeda
b
Chapter 1: Introduces the definition of Non-alcoholic Steatohepatitis, market overview.
Chapter 2: Global Non-alcoholic Steatohepatitis market size in revenue.
Chapter 3: Detailed analysis of Non-alcoholic Steatohepatitis company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-alcoholic Steatohepatitis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Non-alcoholic Steatohepatitis Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 2388.1 million
|
| Forecast Market size by 2030 |
US$ 9466.4 million
|
| Growth Rate |
CAGR of 21.7% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
110 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-alcoholic Steatohepatitis Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-alcoholic Steatohepatitis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-alcoholic Steatohepatitis Overall Market Size
2.1 Global Non-alcoholic Steatohepatitis Market Size: 2023 VS 2030
2.2 Global Non-alcoholic Steatohepatitis Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-alcoholic Steatohepatitis Players in Global Market
3.2 Top Global Non-alcoholic Steatohepatitis Companies Ranked by Revenue
3.3 Global Non-alcoholic Steatohepatitis Revenue by Companies
3.4 Top 3 and Top 5 Non-alcoholic Steatohepatitis Companies in Global Market, by Revenue in 2023
3.5 Global Companies Non-alcoholic Steatohepatitis Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-alcoholic Steatohepatitis Players in Global Market
3.6.1 List of Global Tier 1 Non-alcoholic Steatohepatitis Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-alcoholic Steatohepatitis Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-alcoholic Steatohepatitis Market Size Markets, 2023 & 2030
4.1.2 Solid
4.1.3 Liquid
4.2 By Type - Global Non-alcoholic Steatohepatitis Revenue & Forecasts
4.2.1 By Type - Global Non-alcoholic Steatohepatitis Revenue, 2019-2024
4.2.2 By Type - Global Non-alcoholic Steatohepatitis Revenue, 2025-2030
4.2.3 By Type - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-alcoholic Steatohepatitis Market Size, 2023 & 2030
5.1.2 Oral
5.1.3 Parenteral
5.2 By Application - Global Non-alcoholic Steatohepatitis Revenue & Forecasts
5.2.1 By Application - Global Non-alcoholic Steatohepatitis Revenue, 2019-2024
5.2.2 By Application - Global Non-alcoholic Steatohepatitis Revenue, 2025-2030
5.2.3 By Application - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Non-alcoholic Steatohepatitis Market Size, 2023 & 2030
6.2 By Region - Global Non-alcoholic Steatohepatitis Revenue & Forecasts
6.2.1 By Region - Global Non-alcoholic Steatohepatitis Revenue, 2019-2024
6.2.2 By Region - Global Non-alcoholic Steatohepatitis Revenue, 2025-2030
6.2.3 By Region - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Non-alcoholic Steatohepatitis Revenue, 2019-2030
6.3.2 US Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.3.3 Canada Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.3.4 Mexico Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Non-alcoholic Steatohepatitis Revenue, 2019-2030
6.4.2 Germany Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4.3 France Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4.4 U.K. Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4.5 Italy Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4.6 Russia Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4.7 Nordic Countries Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.4.8 Benelux Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Non-alcoholic Steatohepatitis Revenue, 2019-2030
6.5.2 China Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.5.3 Japan Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.5.4 South Korea Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.5.5 Southeast Asia Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.5.6 India Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Non-alcoholic Steatohepatitis Revenue, 2019-2030
6.6.2 Brazil Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.6.3 Argentina Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-alcoholic Steatohepatitis Revenue, 2019-2030
6.7.2 Turkey Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.7.3 Israel Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.7.4 Saudi Arabia Non-alcoholic Steatohepatitis Market Size, 2019-2030
6.7.5 UAE Non-alcoholic Steatohepatitis Market Size, 2019-2030
7 Non-alcoholic Steatohepatitis Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Non-alcoholic Steatohepatitis Major Product Offerings
7.1.4 AstraZeneca Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Non-alcoholic Steatohepatitis Major Product Offerings
7.2.4 Pfizer Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.2.5 Pfizer Key News & Latest Developments
7.3 GSK
7.3.1 GSK Company Summary
7.3.2 GSK Business Overview
7.3.3 GSK Non-alcoholic Steatohepatitis Major Product Offerings
7.3.4 GSK Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.3.5 GSK Key News & Latest Developments
7.4 Novo Nordisk
7.4.1 Novo Nordisk Company Summary
7.4.2 Novo Nordisk Business Overview
7.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Major Product Offerings
7.4.4 Novo Nordisk Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.4.5 Novo Nordisk Key News & Latest Developments
7.5 Roche
7.5.1 Roche Company Summary
7.5.2 Roche Business Overview
7.5.3 Roche Non-alcoholic Steatohepatitis Major Product Offerings
7.5.4 Roche Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.5.5 Roche Key News & Latest Developments
7.6 AbbVie
7.6.1 AbbVie Company Summary
7.6.2 AbbVie Business Overview
7.6.3 AbbVie Non-alcoholic Steatohepatitis Major Product Offerings
7.6.4 AbbVie Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.6.5 AbbVie Key News & Latest Developments
7.7 Galectin Therapeutics
7.7.1 Galectin Therapeutics Company Summary
7.7.2 Galectin Therapeutics Business Overview
7.7.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Major Product Offerings
7.7.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.7.5 Galectin Therapeutics Key News & Latest Developments
7.8 Galmed Pharmaceuticals
7.8.1 Galmed Pharmaceuticals Company Summary
7.8.2 Galmed Pharmaceuticals Business Overview
7.8.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Major Product Offerings
7.8.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.8.5 Galmed Pharmaceuticals Key News & Latest Developments
7.9 Gilead
7.9.1 Gilead Company Summary
7.9.2 Gilead Business Overview
7.9.3 Gilead Non-alcoholic Steatohepatitis Major Product Offerings
7.9.4 Gilead Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.9.5 Gilead Key News & Latest Developments
7.10 Intercept pharma
7.10.1 Intercept pharma Company Summary
7.10.2 Intercept pharma Business Overview
7.10.3 Intercept pharma Non-alcoholic Steatohepatitis Major Product Offerings
7.10.4 Intercept pharma Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.10.5 Intercept pharma Key News & Latest Developments
7.11 Non-alcoholic Steatohepatitis
7.11.1 Non-alcoholic Steatohepatitis Company Summary
7.11.2 Non-alcoholic Steatohepatitis Business Overview
7.11.3 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Major Product Offerings
7.11.4 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.11.5 Non-alcoholic Steatohepatitis Key News & Latest Developments
7.12 Takeda
7.12.1 Takeda Company Summary
7.12.2 Takeda Business Overview
7.12.3 Takeda Non-alcoholic Steatohepatitis Major Product Offerings
7.12.4 Takeda Non-alcoholic Steatohepatitis Revenue in Global Market (2019-2024)
7.12.5 Takeda Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-alcoholic Steatohepatitis Market Opportunities & Trends in Global Market
Table 2. Non-alcoholic Steatohepatitis Market Drivers in Global Market
Table 3. Non-alcoholic Steatohepatitis Market Restraints in Global Market
Table 4. Key Players of Non-alcoholic Steatohepatitis in Global Market
Table 5. Top Non-alcoholic Steatohepatitis Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Non-alcoholic Steatohepatitis Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Non-alcoholic Steatohepatitis Revenue Share by Companies, 2019-2024
Table 8. Global Companies Non-alcoholic Steatohepatitis Product Type
Table 9. List of Global Tier 1 Non-alcoholic Steatohepatitis Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-alcoholic Steatohepatitis Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Non-alcoholic Steatohepatitis Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Non-alcoholic Steatohepatitis Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Non-alcoholic Steatohepatitis Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Non-alcoholic Steatohepatitis Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Non-alcoholic Steatohepatitis Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Non-alcoholic Steatohepatitis Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2025-2030
Table 30. AstraZeneca Company Summary
Table 31. AstraZeneca Non-alcoholic Steatohepatitis Product Offerings
Table 32. AstraZeneca Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 33. AstraZeneca Key News & Latest Developments
Table 34. Pfizer Company Summary
Table 35. Pfizer Non-alcoholic Steatohepatitis Product Offerings
Table 36. Pfizer Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 37. Pfizer Key News & Latest Developments
Table 38. GSK Company Summary
Table 39. GSK Non-alcoholic Steatohepatitis Product Offerings
Table 40. GSK Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 41. GSK Key News & Latest Developments
Table 42. Novo Nordisk Company Summary
Table 43. Novo Nordisk Non-alcoholic Steatohepatitis Product Offerings
Table 44. Novo Nordisk Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 45. Novo Nordisk Key News & Latest Developments
Table 46. Roche Company Summary
Table 47. Roche Non-alcoholic Steatohepatitis Product Offerings
Table 48. Roche Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 49. Roche Key News & Latest Developments
Table 50. AbbVie Company Summary
Table 51. AbbVie Non-alcoholic Steatohepatitis Product Offerings
Table 52. AbbVie Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 53. AbbVie Key News & Latest Developments
Table 54. Galectin Therapeutics Company Summary
Table 55. Galectin Therapeutics Non-alcoholic Steatohepatitis Product Offerings
Table 56. Galectin Therapeutics Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 57. Galectin Therapeutics Key News & Latest Developments
Table 58. Galmed Pharmaceuticals Company Summary
Table 59. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Offerings
Table 60. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 61. Galmed Pharmaceuticals Key News & Latest Developments
Table 62. Gilead Company Summary
Table 63. Gilead Non-alcoholic Steatohepatitis Product Offerings
Table 64. Gilead Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 65. Gilead Key News & Latest Developments
Table 66. Intercept pharma Company Summary
Table 67. Intercept pharma Non-alcoholic Steatohepatitis Product Offerings
Table 68. Intercept pharma Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 69. Intercept pharma Key News & Latest Developments
Table 70. Non-alcoholic Steatohepatitis Company Summary
Table 71. Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Product Offerings
Table 72. Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 73. Non-alcoholic Steatohepatitis Key News & Latest Developments
Table 74. Takeda Company Summary
Table 75. Takeda Non-alcoholic Steatohepatitis Product Offerings
Table 76. Takeda Non-alcoholic Steatohepatitis Revenue (US$, Mn) & (2019-2024)
Table 77. Takeda Key News & Latest Developments
List of Figures
Figure 1. Non-alcoholic Steatohepatitis Segment by Type in 2023
Figure 2. Non-alcoholic Steatohepatitis Segment by Application in 2023
Figure 3. Global Non-alcoholic Steatohepatitis Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Non-alcoholic Steatohepatitis Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Non-alcoholic Steatohepatitis Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-alcoholic Steatohepatitis Revenue in 2023
Figure 8. By Type - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 9. By Application - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 10. By Type - Global Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 12. By Application - Global Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 14. By Region - Global Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 15. By Country - North America Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 16. US Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 20. Germany Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 21. France Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 28. China Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 32. India Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 34. Brazil Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Non-alcoholic Steatohepatitis Revenue Market Share, 2019-2030
Figure 37. Turkey Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Non-alcoholic Steatohepatitis Revenue, (US$, Mn), 2019-2030
Figure 41. AstraZeneca Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Pfizer Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. GSK Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Novo Nordisk Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Roche Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. AbbVie Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Galectin Therapeutics Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Gilead Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Intercept pharma Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Takeda Non-alcoholic Steatohepatitis Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
